STATEMENTS OF STOCKHOLDERS' DEFICIT - 3 months ended May. 31, 2015 - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2015	$ 131,449	$ 114,993,920	$ (115,263,712)	$ (138,343)
Balance (in shares) at Feb. 28, 2015	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D. and related parties		76,783		76,783
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.		555,263		555,263
Net loss			(624,525)	(624,525)
Balance at May. 31, 2015	$ 131,449	$ 115,625,966	$ (115,888,237)	$ (130,822)
Balance (in shares) at May. 31, 2015	131,448,444